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min. Our study indicates that pure curcumin attenuates WT1 auto-regulatory function through inhi-
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The Wilms’ tumor 1 (WT1) gene encodes a DNA-binding tran-
scription factor essential for embryonal development [1–3]. High
levels of WT1 are detected in most cases of chronic myelogeous
leukemia (CML) in blast crisis and acute human leukemia, as well
as leukemic cell lines. First discovered in 1990 and thought to func-
tion as a tumor suppressor, the WT1 transcription factor regulatory
activity has been extensively studied to support a role for WT1 in
oncogenesis [4].
Turmeric (Curcuma longa Linn) is one of the most popular
medicinal herbs, due to its anti-inﬂammatory, antioxidant, anticar-
cinogen, anti-mutagen, and anticancer properties. The active
constituents of turmeric are known as curcuminoids, yellow
pigmented substances isolated from the rhizome of turmeric.
Curcuminoids consist of three distinct components: curcumin,
demethoxycurcumin, and bisdemethoxycurcumin. Curcumin has
strong anticancer and antitumor progression properties [5]. Never-
theless, many biological functions of curcumin result from its
effects on PKC. For example, curcumin opposes the ability of phor-
bol esters to activate PKC in 3T3 cells [6], to promote tumor growthchemical Societies. Published by E
er Center, Research Building
A. Fax: +1 916 734 0190 (C.A.
ent of Medical Technology,
niversity, Chiang Mai 50200,
Sweeney), sanuchapreeda@[7], and to activate the NF-jB and c-jun/AP-1 [8]. Moreover, the
effects of curcumin are similar to the effects of PKC inhibitors: both
curcumin and staurosporine inhibit the function of c-jun/AP-1 [8]
and induce apoptosis in transformed cell lines [9].
Protein kinase C (PKC) is a family of serine/threonine protein
kinases involved in regulating cell growth, differentiation, metabo-
lism, and apoptosis [10]. Pure curcumin has been reported to affect
multiple cell signaling pathways including the PKC signaling
pathway [11–13]. Curcuminoids are a group of diet-derived agents
that are being clinically evaluated as chemopreventive agents for
several cancer types as well as leukemias [14,15]. Pure curcumin
was recently shown to repress WT1 gene expression in both pri-
mary and leukemic cells [16].
Our current study indicates that one anti-proliferative mecha-
nism of pure curcumin is through attenuation of WT1 auto-regula-
tion by inhibiting PKCa signaling.
2. Materials and methods
2.1. Cell culture
Human leukemic cell lines K562 (kindly provided by Dr. Chaisu-
ree Supawilai, Research Institute for Health Sciences, Chiang Mai,
Thailand) was cultured in RPMI 1640 (Invitrogen, CA, USA), supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) (Invit-
rogen, CA, USA) and incubated at 37 C.
Eukaryotic expression vector pcDNA3.1 carrying the cDNA for
WT1 [17AA(+)KTS(+)] or WT1(+/+), WT1 [(17AA(+)KTS()] orlsevier B.V. All rights reserved.
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[17AA()KTS()] or WT1 / were kindly provided by Prof. Dr.
Haruo Sugiyama and Assoc. Prof. Dr. Yusuke Oji, Osaka University
Graduate School of Medicines, Osaka, Japan [17].
2.2. Extraction and isolation of pure curcumin
Pure curcumin was puriﬁed from turmeric powder using col-
umn chromatography. Pure curcumin extraction and isolation
were performed as previously described [18,19].
2.3. Proliferation and viability assay
Cell viability was assessed by the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay (Sigma–Aldrich,
MO, USA) as described previously [20]. The reaction is catalyzed
by mitochondrial succinate dehydrogenase and requires NADH,
which must be supplied by living cells.
Cell proliferation was measured by the trypan blue exclusion
method. Cells were transfected with pcDNA3.1 or four different
WT1 isoforms for 48 h and treated with 25 lM pure curcumin or
0.04% DMSO for 48 h. Then cells and 0.4% trypan blue dye were
mixed and counted using a light microscope. All experiments were
performed in triplicate.
2.4. RNA isolation, reverse transcription and real-time PCR analysis
The K562 cells were treated with pure curcumin and then har-
vested and RNA was isolated using RNeasy Mini Kit (Qiagen, CA,
USA) according to the manufacturer’s protocol. The cDNA was syn-
thesized from 5 lg of total RNA using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystem, CA, USA) with random hexa-
mer primers according to the manufacture’s instruction. Real-time
analysis was carried out with a BioRad iCycler iQ real Time PCR
instrument with TaqMan probe-based chemistry for WT1
(Hs01103754) and GAPDH (Hs99999905) (Applied Biosystem, CA,
USA) using Two Step RT qPCR Master Mix (Applied Biosystem,
CA, USA).
2.5. Preparation of membrane fractions
To detect the activated (membrane associated) fraction of PKCa
in treated K562 cells, cells were washed twice with PBS and then
washed with buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, and 0.5 mM DTT). The cell pellets were resuspended in buf-
fer A containing 0.1% Nonidet P40 and homogenized using a coni-
cal homogenizer and then incubated on ice for 30 min. After
30 min, the cell homogenates were centrifuged at 2900g for
20 min. The supernatant was collected and centrifuged at
100 000g, 4 C for 1 h. The supernatant of this spin was collected
as the cytosolic fraction. The pellets (considered the membrane
fraction) were resuspended in RIPA buffer (50 mM Tris, 0.1% SDS,
1% Triton X-100, 150 mM NaCl, and 0.5 mM EDTA) containing pro-
tease inhibitors and then the protein concentrations were mea-
sured by Lowry’s method (DC Protein Assay Kit; BioRad, CA, USA).
2.6. Preparation of whole lysate protein and immunoblotting
The treated cells were washed twice with PBS and lysed with
cold RIPA buffer containing protease inhibitors and centrifuged.
Fifty micrograms of crude protein or 30 lg of membrane protein
fraction were separated by SDS–PAGE, transferred to nitrocellulose
membrane and blocked in 5% non-fat milk. Membranes were
probed with anti-WT1 antibody (C-19, Santa Cruz, CA, USA), anti
PKC isotype antibody (Cell Signaling Technology, CA, USA) or anti
GAPDH antibody (Santa Cruz, CA, USA). The following secondaryantibodies were used: goat-anti-rabbit-horseradish peroxidase,
goat-anti-mouse-horseradish peroxidase or goat-anti-rat-horse-
radish peroxidase (Invitrogen, CA, USA). Peroxidase activity was
detected using an enhanced chemiluminescence detection kit
(Thermo Scientiﬁc, Miami, USA) and an Alpha Innotech gel imaging
system (Cell Biosciences Inc., CA, USA). Densitometry was per-
formed using Alpha Innotech software.
2.7. Protein and mRNA half life analysis
K562 cells were incubated with 50 lg/ml cycloheximide (CHX)
in the presence or absence of 15 lM pure curcumin. For the protea-
some inhibitor assay, cells were incubated with or without 5 lM
MG132 or 10 lM ()-Epigallocatechin gallate (EGCG) (Sigma–Al-
drich, MO, USA) or 10 lM Lactacystin (TRC, Ontario, Canada) in
the presence or absence of 15 lM pure curcumin for 12 h. K562
mRNA stability was assessed with 4 lM actinomycin D in the pres-
ence and absence of 15 lMpure curcumin. For PKCa inhibitor treat-
ment, K562 cells were incubatedwith 0.0084 lMGF109203x (IC50).
2.8. Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assay previously described
[21], was used to detect interaction between transcription factors
and the proximal WT1 promoter. K562 cells were treated with
15 lM pure curcumin or vehicle control for 24 h and crosslinked
with 1% formaldehyde. For the immunoprecipitation, anti-WT1
(C-19) antibody, anti-Sp1 antibody (Santa Cruz, CA, USA) or anti
mouse IgG antibody (MP Biomedical, OH, USA) were added and
incubated overnight at 4 C. The chromatin immunoprecipitated
DNA was ampliﬁed by standard PCR or ChIP-qPCR using SYBR
Green Master Mix (BioRad, CA, USA). WT1 primer: 50-CCTGAACG-
GACTCTCCAGTG-30 (forward) and 50-CGCTGCCTTGAACTCCTTAC-30
(reverse). The WT1 promoter sequences were referenced from
GenBank™ Accession No. U77682 and based on DNA sequence
published in Fraizer et al. [22].
2.9. Transient transfections
DNA plasmid vector containing Myr.PKCa (Addgene, MA, USA)
was transfected into K562 cells by Lipofectamine™ LTX with Plus™
reagent (Invitrogen, CA, USA). After 48 h, the transfected cells were
treated with 15 lM pure curcumin for 24 h.
2.10. Promoter luciferase-reporter assays
K562 cells were plated in 12-well dish format and transfected
the next day with 1 lg of the proximal WT1 pGL3 Basic luciferase
reporter construct (kindly provided by Prof. Dr. Takashi Murate)
[23] and 80 ng beta-galactosidase pCMX vector by Lipofectamine™
LTXwith Plus™ reagent (Invitrogen, CA, USA) according to theman-
ufacturer’s instructions. After 6 h, the cells were treated with pure
curcumin for 24 h, lysed in Reporter Lysis Buffer and the ﬁreﬂy lucif-
erase activity measured using the Luciferase Assay Kit (Promega,
WI, USA) on a Veritas 96 Microplate Luminometer (Promega, WI,
USA). The ﬁreﬂy luciferase was normalized with b-galactosidase
activity to control for transfection efﬁciency. For the mutant pGL3
construct, core nucleotides of the putative WT1 binding site in the
promoterwere altered byQuick-Change SiteMutagenesis Kit (Invit-
rogen, CA, USA) using PCR primers for WT1 consensus sequence:
50 to 39 GTGTGGGAGCC [24] was mutated to ATATGATATCA.
2.11. Statistical analysis
Statistical analysis was performed with SPSS software (version
10.0). All experiments were performed in duplicate and repeated
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Fig. 1. Effect of pure curcumin on WT1 gene expression in K562 cells. The level of WT1 protein expression was assessed by immunoblotting after treatment with various
doses of pure curcumin for 24 h, shown in (A). Time course with 15 lM pure curcumin assayed at 0, 3, 6, 12, and 24 h, shown in (B). GAPDH was used as loading control.
Densitometry was used to quantify the protein levels and graphed as the percentage of vehicle control. Data are the mean value ± S.E.M. of three independent experiments.
Asterisks () denote values that were signiﬁcantly different from the vehicle control (P < 0.05).
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Fig. 2. Effect of pure curcumin on WT1 protein and mRNA stability. To investigate the effect of pure curcumin on protein stability, K562 cells were treated with 50 lg/ml
cycloheximide in the presence or absence of 15 lM pure curcumin for 0, 3, 6, 12, and 24 h and assessed by immunoblotting, as shown in (A). WT1 protein levels from three
independent experiments were quantiﬁed and shown in (B). (C) The effect of 15 lM pure curcumin on WT1 protein levels was examined in the presence or absence of 5 lM
MG132. GAPDH was used as loading control. (D) K562 cells were treated with 4 lM actinomycin D in the presence or absence of 15 lM pure curcumin for 0, 6, and 12 h and
WT1 mRNA was assayed by Taqman qRT-PCR. GAPDH was used as an internal control. Data are the mean value ± S.E.M. of three independent experiments. Asterisks ()
denote values that were signiﬁcantly different from the vehicle control (P < 0.05).
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2238 S. Semsri et al. / FEBS Letters 585 (2011) 2235–2242at least three times. The data were expressed as the mean ± stan-
dard error of sample mean (S.E.M.). Statistical differences between
the means were tested by one-way ANOVA. Probability values
P < 0.05 were considered signiﬁcant.
3. Results
3.1. Effect of pure curcumin on WT1 gene expression is not through
protein or mRNA degradation pathways
The pure curcumin derivative of curcumunoids was previously
shown to suppress the WT1 transcription factor mRNA and protein
levels in several leukemic cell lines [16]. We ﬁrst conﬁrmed WT1
down-regulation by pure curcumin in a dose response and time
course in K562 cells for this study (Fig. 1A and B). K562 cells were
treated with pure curcumin at 15 lM (IC20) or 25 lM (IC50) for
24 h, or as indicated. To determine whether pure curcumin has
any effect on WT1 protein stability, we performed a time course
experiment with the protein synthesis inhibitor, cyclohexamide
(CHX), to determine the half life of WT1 protein. The half life of
WT1 protein treated with vehicle control at 12.6 h was not signif-
icantly different compared to cells treated with 15 lM pure curcu-
min at 14.4 h (Fig. 2A and B). In addition, we treated K562 cells
with pure curcumin in the presence or absence of the proteasome
inhibitors MG132, ()-Epigallocatechin gallate (EGCG), and Lacta-
cystin to determine whether proteasome inhibition would inter-
fere with the repressive effect of pure curcumin on WT1 (Fig. 2C
and Supplementary Fig. 1). WT1 protein expression decreased
similarly after treatment with pure curcumin in the presence or
absence of MG132 or EGCG or Lactacystin, indicating that the purecurcumin-mediated down-regulation of WT1 protein is not
through proteasomal degradation pathways. Since pure curcumin
has been shown to decrease WT1 mRNA levels [20], we examined
whether WT1 mRNA stability was affected. K562 cells were treated
with 4 lM actinomycin D and assayed over 12 h in the presence or
absence of pure curcumin. The stability of WT1 mRNA was un-
changed between vehicle-treated and pure curcumin-treated
K562 cells (Fig. 2D). Together these results demonstrate that the
down-regulation of WT1 gene expression by pure curcumin was
independent of protein or mRNA degradation pathways.
3.2. WT1 over-expression reverses the effect of pure curcumin activity
WT1mRNA undergoes alternative splicing at two sites resulting
in fourmRNA species and protein products [25];WT1 +/+,WT1 +/,
WT1 /+, and WT1 / [22]. Since pure curcumin inhibits cell
growth and represses WT1 expression, we sought to determine
whether the two are linked. For this experiment, we determined
whether we could reverse the anti-proliferative effects of pure cur-
cumin by over-expressing exogenous WT1 in K562 cells. The WT1
isoform constructs were transfected into K562 cells and WT1 pro-
tein over-expression relative to vector control was conﬁrmed by
immunoblotting of lysates collected at 48 h after treatment with
25 lM pure curcumin (IC50), as shown in Fig. 3A and C. Next, the
anti-proliferative effect of pure curcumin on K562 cells transfected
with WT1 isoforms was assayed by measurement of cell viability
and proliferation using the MTT assay and trypan blue exclusion
method. The over-expression of all four WT1 isoforms in K562
showed resistance to the anti-proliferative effects of pure
curcumin activity when compared to transfected vector control
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versed the anti-proliferative activity of pure curcumin. This ﬁnding
provides key insight into the growth inhibitorymechanisms of pure
curcumin. Our result also demonstrates the transcriptional redun-
dancy of WT1 isoforms and their regulatory function in cell
proliferation.
3.3. Pure curcumin attenuates WT1 auto-regulation
The WT1 promoter has been extensively analyzed [22] and
shown to auto-regulate itself by the WT1 transcription factor
[24], and by other transcription factors including GATA1 [23,26]
and Sp1 [27]. WT1 also regulates immunosuppressant cytokine
interleukin-10 (IL-10) gene [28]. K562 cells were treated with var-
ious doses of pure curcumin for 24 h and immunoblotted for WT1
and Sp1 protein levels. The pure curcumin concentrations of 10
and 15 lM showed down-regulation of WT1 protein but not Sp1
protein, demonstrating speciﬁcity (Fig. 4B). Next, the effect of pure
curcumin on the interaction between WT1 and Sp1 transcription
factors and the WT1 proximal promoter was investigated by chro-
matin immunoprecipitation assay. Pure curcumin prevented bind-
ing of WT1 to the region containing a WT1 consensus binding site
in the proximal promoter (see schematic in Fig. 4A; promoter se-
quence [22]) as shown by standard PCR (Fig. 4C) or ChIP qPCR
(Fig. 4D). The pure curcumin treatment had no effect on the bind-
ing of Sp1 (Fig. 4C and D). The inhibition of WT1-DNA binding but
not Sp1 binding suggests that pure curcumin depletes WT1
through a loss of auto-regulatory function. In other words, purecurcumin disrupts a feed-forward loop in which WT1 promotes
its own expression.
The WT1 ChIP assay demonstrated that pure curcumin abro-
gates WT1 transcription factor binding to the WT1 proximal pro-
moter. To further evaluate the effect of pure curcumin on the
WT1 promoter auto-regulation we obtained a luciferase reporter
construct for the minimal proximal WT1 promoter sequence re-
quired for maximum response in K562 leukemia cells [23]. There
are several potential WT1 and Sp1 consensus sites within the
WT1 proximal promoter [22]. The WT1 (50 to 39) and Sp1
(224 to 203) consensus binding sites included within the
301 bp reporter construct are indicated (see schematic of se-
quence; Supplementary information). Transfection of the 301 bp
construct into K562 cells demonstrated high luciferase activity
with vehicle-control treated cells and a diminished response from
pure curcumin treated K562 cells (Fig. 5A). To determine if the
luciferase activity was driven by WT1 protein binding to the prox-
imal promoter, the WT1 binding site located at 50 to 39 was
mutated. Importantly, the luciferase construct containing the mu-
tated WT1 binding site in the proximal WT1 promoter was much
less responsive when transfected into K562 cells (Fig. 5B) suggest-
ingWT1 binding to the proximal promoter was driving ﬁreﬂy lucif-
erase expression. The WT1 binding site included within the
luciferase reporter construct and the ChIP-qPCR ampliﬁed region
suggest that the inhibitory effect of pure curcumin on WT1 auto-
regulation is mediated at least in part through the upstream
WT1 binding site located at position 50 to 39 in the WT1 prox-
imal promoter.
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pathway
Pure curcumin has been shown to inhibit PKC signaling and to
inhibit WT1 expression in independent studies [11,16]. We next
investigated whether the down-regulation ofWT1 gene expression
by pure curcumin is through an inhibition of the PKCa signaling
pathway. Preliminary data from phospho-kinase arrays (R&D Sys-
tem, MN, USA) probed with K562 lysates indicated decreased phos-
pho-c-Jun and phosho-JNKpan (PKC targets) from pure curcumin
treated compared to control-treated cells (Supplementary Fig. 2).
To determine if PKCa is actively functioning at the cell membrane
in K562 cells, we prepared cell membrane protein fractions and
immunoblotted for PKCa or the membrane protein, caveolin 3, in
K562 cells treated with pure curcumin or vehicle control. The
immunoblot shows 15 lM pure curcumin signiﬁcantly decreased
PKCa occupancy at the membrane but had no effect on caveolin
3 expression (Fig. 6A).
To test whether inhibition of PKCamimics pure curcumin treat-
ment with respect to WT1 expression, we assayed WT1 protein
levels after treatment with the PKCa protein kinase inhibitor
(GF109203x) at several time points in K562 cells. The immunoblot
shown in Fig. 6B indicates inhibition of PKCa activity decreased
WT1protein after 3 h of GF109203x treatment and the level of pro-
tein expression remained decreased at 5 and 7 h (Fig. 6B).
3.5. PKCa activation up-regulates WT1 expression and reverses pure
curcumin inhibition of WT1 expression in K562 cells
We next investigated whether PKCa activation could induce an
increase in endogenous WT1 protein in K562 cells and reverse thepure curcumin effect on WT1 expression. K562 cells were transfec-
ted with Myr.PKCa vector or control vector for 48 h and treated
with or without 15 lM pure curcumin for 24 h. The Myr.PKCa
transfected K562 cells demonstrated an up-regulation of endoge-
nous WT1 protein expression when compared to control transfec-
ted cells. The control transfected K562 treated with pure curcumin
showed down-regulated endogenous WT1 protein as expected,
and duplicated our previous results shown in Fig. 1A. In contrast,
the Myr.PKCa transfected K562 cells increased endogenous WT1
expression and reversed the pure curcumin inhibitory effect on
WT1 (Fig. 6C). In other words, in the presence of activated PKCa,
pure curcumin was unable to suppress WT1 expression. This result
provides a novel functional link between pure curcumin-mediated
inhibition of PKCa and pure curcumin-mediated repression of
WT1.
4. Discussion
Expression of the Wilms’ tumor 1 gene product has been shown
to increase 1000–10 000 fold in leukemic cells [29,30], suggesting
that the WT1 gene may play an important role in oncogenesis. In
anticancer drug research, dietary and/or medicinal plants, such as
turmeric, ginger, garlic, chili, and pepper are becoming popular
as chemotherapeutic and/or chemopreventative drugs. Curcumin
is the main active ingredient of turmeric, a traditional herbal med-
icine and food of south Asia. Curcumin has been reported to affect
multiple cell signaling pathways [31], and recent studies indicate
curcumin inhibits WT1 expression in leukemic cell lines [16] and
PANC-1 pancreatic cancer cells [32].
Previous work showed pure curcumin decreased WT1 mRNA
and WT1 protein levels in several human leukemic cell lines
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Fig. 6. The effect of pure curcumin on PKC signaling. (A) K562 cells were treated with 15 lM pure curcumin for 24 h and the membrane fraction collected and immunoblotted
for levels of PKCa or the membrane protein, caveolin 3. (B) The effect of PKCa inhibitor on WT1 expression in K562 cells assayed after treatment with 0.0084 lM GF109203x
(IC50, PKCa inhibitor) at various time points. Immunoblot detection of theWT1 or GAPDH protein levels are shown (top) and densitometry graphed below. (C) K562 cells were
transiently transfected with vector control or Flag-tagged Myr.PKCa. Cells were then treated with vehicle control or 15 lM pure curcumin. Lysates were immunoblotted for
Flag (Myr.PKCa), WT1 or GAPDH loading control. Densitometry graphed as percentage of control treatment (right panel). Data are the mean value ± S.E.M. of three
independent experiments. Asterisks () denote values that were signiﬁcantly different from the vehicle control (P < 0.05).
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study demonstrates that the pure curcumin-mediated down-reg-
ulation of WT1 was not the result of protein or mRNA degrada-
tion processes in the K562 leukemic cell line. Rather, both
Chromatin immunoprecipitation and luciferase reporter assays
indicate that pure curcumin interferes with WT1 binding to its
DNA consensus site at the proximal promoter of the WT1 gene,
nullifying WT1’s positive auto-regulatory role. Further reporter
assays in K562 cells showed mutation of the DNA consensus site
in the proximal promoter of the WT1 gene attenuated WT1-bind-
ing and abolished reporter activity. Together these results demon-
strated pure curcumin interferes with WT1 auto-regulatory
activity, resulting in down-regulation of WT1 expression. Since
ectopic over-expression of WT1 prevents growth inhibition by
pure curcumin (Fig. 3), these results demonstrate that repression
of WT1 is an essential mechanism by which pure curcumin inhib-
its tumor cell growth.
Several studies have shown that curcumin affects multiple sig-
naling pathways, including protein kinase C [13,31,33,34]. We
tested whether the pure curcumin inhibitory effect on WT1 gene
expression is mediated through the PKC signaling pathway. Treat-
ment of K562 cells with the PKC inhibitor, GF109203x, down-reg-
ulated endogenous WT1 expression in K562 cells, mimicking the
results obtained with pure curcumin. In addition, chronic activa-
tion of PKC by expression of Myr.PKCa demonstrated that PKCaactivation rescued the pure curcumin inhibitory effect on WT1
expression.
Our results indicate that pure curcumin interferes with PKC sig-
naling and WT1 expression and that the two are functionally
linked. Both pure curcumin and PKC inhibitor treatment down-reg-
ulated WT1 expression, indicating that WT1 is downstream of the
pure curcumin inhibitory effect on PKC signaling. Over-expression
of Myr.PKCa increased WT1 protein levels and rescued the inhibi-
tory effect of pure curcumin on WT1 expression. Transcription fac-
tor DNA binding is commonly regulated by phosphorylation. Early
in vitro work on WT1 regulation reported that PKC phosphorylates
WT1 at one of several potential sites, inhibiting DNA binding [35].
Our results suggest that PKCa phosphorylation may also enhance
WT1 DNA binding. Interestingly, PKCa and pure curcumin have
been shown to physically interact [13]. The mechanism of how
PKCa positively regulates WT1 expression in K562 cells will re-
quire further investigation.
In conclusion, our results indicate the effect of pure curcumin
on WT1 gene expression in the leukemic K562 cell line was medi-
ated through PKCa signaling upstream of the WT1 transcription
factor auto-regulatory function. As a result, pure curcumin affected
theWT1 protein-promoter binding and the decrease of WT1mRNA
and protein levels in K562 cells contributed to the pure curcumin
anti-proliferative effect. This novel mechanistic knowledge of
how pure curcumin effects WT1 transcriptional function in
2242 S. Semsri et al. / FEBS Letters 585 (2011) 2235–2242leukemic cells may be useful in the future development of thera-
peutic approaches for leukemic patients.
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